Alison Axtman

Alison Axtman

SGC UNC

Axtman

Alison Axtman

(216) 470-7201

Biography

Alison Axtman is a synthetic medicinal chemist with more than 10 years of research experience working at the interface of chemical and biology. Alison earned her PhD in Medicinal Chemistry at the University of Kansas, and carried out her post-doctoral training in the Department of Chemistry at Stanford University. Alison’s research has focused on the synthesis of small molecules that selectively modulate proteins implicated in disease-propagating pathways. As a member of the GSK Chemical Biology department, she led a program to understand the molecular basis of immune modulation by a class of natural products and developed analogs with improved drug properties. Alison is currently a Research Assistant Professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Alison can be most often found at the gym preparing for the next CrossFit or GRID competition with her teammates.

2020

SGC-AAK1-1: A Chemical Probe Targeting AAK1 and BMP2K.

Wells C, Couñago RM, Limas JC, Almeida TL, Cook JG, Drewry DH, Elkins JM, Gileadi O, Kapadia NR, Lorente-Macias A, Pickett JE, Riemen A, Ruela-de-Sousa RR, Willson TM, Zhang C, Zuercher WJ, Zutshi R, Axtman AD

ACS Med Chem Lett. 2020-3-12 . 11(3):340-345 .doi: 10.1021/acsmedchemlett.9b00399

PMID: 32184967

2019

CDK16: the pick of the understudied PCTAIRE kinases.

Axtman A, Drewry D, Wells C

Nat Rev Drug Discov. 2019-7-4 . 18(7):489 .doi: 10.1038/d41573-019-00076-x

PMID: 31267068

WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop.

Agajanian MJ, Walker MP, Axtman AD, Ruela-de-Sousa RR, Serafin DS, Rabinowitz AD, Graham DM, Ryan MB, Tamir T, Nakamichi Y, Gammons MV, Bennett JM, Couñago RM, Drewry DH, Elkins JM, Gileadi C, Gileadi O, Godoi PH, Kapadia N, Müller S, Santiago AS, Sorrell FJ, Wells CI, Fedorov O, Willson TM, Zuercher WJ, Major MB

Cell Rep. 2019-1-2 . 26(1):79-93.e8 .doi: 10.1016/j.celrep.2018.12.023

PMID: 30605688

2018

Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1.

Jamieson SA, Ruan Z, Burgess AE, Curry JR, McMillan HD, Brewster JL, Dunbier AK, Axtman AD, Kannan N, Mace PD

Sci Signal. 2018-9-25 . 11(549): .doi: 10.1126/scisignal.aau0597

PMID: 30254053

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM

SLAS Discov. 2018-5-1 . 2472555218773045 .doi: 10.1177/2472555218773045

PMID: 29742358

2017

Progress towards a public chemogenomic set for protein kinases and a call for contributions.

Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM

PLoS ONE. 2017-8-3 . 12(8):e0181585 .doi: 10.1371/journal.pone.0181585

PMID: 28767711